



An Information Service of the Division of Health Benefits

NC Medicaid Pharmacy Newsletter

Number 394

October 2026

In This Issue

**[Drug Enforcement Administration \(DEA\) Certification Required for Prescribing
Controlled Substances](#)**

[Participation in the CMS GENEROUS Model](#)

[Medicare Part D Coverage for Dual-Eligible Beneficiaries](#)

[Vaya and Partners Merger Effective October 1, 2026](#)

[Opill Without a Prescription Pharmacy Coverage](#)

[Billing Remainder of a Third-Party Prescription to Medicaid](#)

[Use of the Pharmacy NPI for POS Protocol Claims Ended May 2, 2026](#)

[72-Hour Emergency Supply Available for Pharmacy Prior Authorization Drugs](#)

[Checkwrite Schedule for October 2026](#)

[October 1, 2026 Preferred Drug List \(PDL\) Changes](#)

[Preferred Brands with Non-Preferred Generics on the Preferred Drug List \(PDL\)](#)

Did you know... You can locate override codes in the Pharmacy Provider Manual on the Provider Portal: [**North Carolina Medicaid Direct Pharmacy Provider Manual**](#)

Drug Enforcement Administration Certification Required for Prescribing Controlled Substances

Beginning Nov. 1, 2026, pharmacy claims for controlled substances will be denied if the prescriber does not have an active Drug Enforcement Administration (DEA) certification on their NCTracks provider enrollment record.

Pharmacies may receive reject code “25 – M/I Prescriber ID” with the additional message "Missing or Invalid DEA certification on record. Prescribers should contact NCTracks to update their DEA record on file." Pharmacy providers should advise prescribers to update their DEA certification on file with NCTracks. Prime Therapeutics will not provide overrides for claims denied with this reject code.

Prescribers can submit a Manage Change Request (MCR) through the NCTracks Secure Provider Portal. An MCR typically takes seven to 10 business days to process. Pharmacy providers should request a new prescription from an authorized provider if the Medicaid beneficiary needs their prescription before the MCR is processed.

Participation in the CMS GENEROUS Model

NC Medicaid has officially signed the State Participation Agreement and is now actively engaged in the CMS GENEROUS Model. The GENEROUS Model (short for *GENErating cost Reductions FOR US Medicaid*) is a voluntary federal initiative designed to lower Medicaid drug spending through internationally referenced Most Favored Nation pricing. The model began on **Jan. 1, 2026**, and will run through **Dec. 31, 2030**.

Through this initiative, CMS negotiates pricing and key coverage terms with participating manufacturers, providing states with access to nationally negotiated arrangements intended to reduce drug costs and expand access to important therapies. NC Medicaid maintains the flexibility to **select drugs that offer the best value**, ensuring thoughtful and targeted adoption of products that support improved access and quality. North Carolina remains committed to advancing lower costs and stronger value for the people we serve, while supporting improved access to affordable medications for Medicaid beneficiaries.

Medicare Part D Coverage for Dual-Eligible Beneficiaries

Medicare Part D is the primary payer for Part D-covered prescription medications for beneficiaries who have both Medicare and NC Medicaid. NC Medicaid does not cover Medicare Part D copays.

Beneficiaries with full Medicaid coverage automatically qualify for Medicare Extra Help, also known as the Low-Income Subsidy (LIS). Beneficiaries who qualify for Medicaid or Extra Help but do not yet have Medicare Part D coverage may qualify for temporary prescription drug coverage through the Limited Income Newly Eligible Transition (LINET) program.

What Pharmacy Providers Should Do When a Medicaid Beneficiary Has Medicare:

Verify Medicare Part D Enrollment

Submit an E1 eligibility query using the beneficiary's Medicare information. Part D plan enrollment information may be available up to 90 days before the query.

- If the E1 query identifies a Medicare Part D plan, submit the claim to that plan using the BIN and PCN provided.
- If the E1 query does not identify a Part D plan, continue to Step 2.

Verify eligibility for Medicare and Medicaid or Extra Help

Verify eligibility using:

- Medicaid ID card
- Current Medicaid award letter with effective dates
- State eligibility verification system
- Notice from Medicare or the Social Security Administration awarding Extra Help

Submit the claim to LINET if the beneficiary is eligible

- **BIN:** 015599
- **PCN:** 05440000
- **Group ID:** Leave Blank
- **Cardholder ID:** Medicare Beneficiary Identifier (MBI) from the beneficiary's Medicare card or the ID returned on the E1 eligibility query

If the beneficiary cannot provide evidence of current Medicare and Medicaid or Extra Help eligibility, do not submit the LINET claim. Refer the beneficiary to the Seniors' Health Insurance Information Program (SHIIP) for help.

For LINET claims or eligibility assistance, call the Humana LINET Service Center at **1-800-783-1307**, Monday through Friday, 8 a.m. to 5 p.m.

Vaya and Partners Merge

Vaya and Partners, two of NC Medicaid's Tailored Plans, merged on Oct. 1, 2026. The merged plan operates under the name Vaya Partners. Vaya Partners serves members across 47 counties.

Beneficiaries previously enrolled in Vaya or Partners were automatically enrolled in Vaya Partners. Prescription claims for Vaya Partners members will process through Navitus, the current pharmacy benefit manager (PBM) for Vaya.

PBM information for all PHPs is found on the [Pharmacy Services Webpage](#).

Follow the billing guidance for PBM Processor Navitus when submitting claims for Vaya Partners members.

Opill Available Without a Prescription at No Cost

The over-the-counter (OTC) oral contraceptive Opill is available *without a prescription*, at no cost to eligible NC Medicaid beneficiaries.

Although NC Medicaid encourages beneficiaries to establish care with a medical home, coverage without a prescription allows Medicaid beneficiaries easy access to Opill and reduces barriers such as scheduling an appointment to obtain a prescription, arranging transportation, or limited access to health care providers in their communities. Medicaid beneficiaries may obtain Opill from NC Medicaid enrolled pharmacies, which can submit claims for reimbursement.

Billing Remainder of a Third-Party Prescription to Medicaid

As required by federal law, Medicaid is the “payer of last resort.” Pharmacies should submit claims to applicable third-party insurance carriers, including Medicare and private health insurance plans, before submitting claims to Medicaid for processing. Additionally, providers must report payment or denial information from third-party insurers when submitting claims for Medicaid payment.

When a pharmacy claim is submitted, the pharmacy benefit administrator checks for third-party coverage on the member's eligibility file. If coverage is found, the claim is denied for “other coverage,” and a message is returned by the point-of-sale (POS) system informing the provider that the beneficiary has third-party coverage for that date of service. The third party insurer must be billed as the primary payor, then Medicaid can be billed as the secondary payor.

If a beneficiary cannot provide information about another insurance coverage or states that they do not have other insurance, the pharmacy may use an applicable override code to

process the claim for Medicaid payment. Enter the appropriate code in Claim Segment 308-C8 (Other Coverage Code)”.

If an appropriate override code is used, NC Medicaid pays the pharmacy and pursues reimbursement from the third-party insurer, as applicable. for payment. The pharmacy cannot be held liable for any payments made in these cases.

Code	Suggested Description
01	No Other Coverage Identified
02	Other Coverage Exists - Payment Collected (the member has other coverage, and the payor has returned a payment amount)
03	Other Coverage Exists - This Claim Not Covered (claim not covered under primary Third-Party Plan)
04	Other Coverage Exists - Payment Not Collected (used when the member has other coverage and that payor has accepted the claim but did not return any payment.

Refer to Pharmacy Clinical Coverage Policy No. 9 at medicaid.ncdhhs.gov/providers/program-specific-clinical-coverage-policies for additional guidance on cost avoidance.

*Codes may vary by managed care plan. These are the specific codes for NC Medicaid Direct.

Use of the Pharmacy NPI for POS Protocol Claims Ended May 2, 2026

Since August 2023, when the State Health Director Standing Orders ended and the Statewide Board of Pharmacy Protocols became effective, pharmacies have been permitted to use the pharmacy NPI as the prescriber on point-of-sale (POS) claims for protocol medications. This temporary allowance ended May 2, 2026.

This allowance was necessary to facilitate payment for claims submitted when dispensing medications under an authorized protocol. For additional information about this transition, refer to the [August 2023 Pharmacy Newsletter](#) article, “State Health Director Standing Orders to be replaced by State Protocols in August 2023” An excerpt from the August 2023 article follows.

“The protocols are intended for pharmacist use; however, immunizing pharmacists are not currently enrolled providers in NC Medicaid. Until pharmacists have the ability to enroll in NC Medicaid as a provider, the pharmacy NPI should be used as the prescriber when utilizing the protocols for an NC Medicaid beneficiary...”

Effective **May 2, 2026**, the pharmacy NPI is not allowed in the prescriber field on POS claims for any of following five categories of [Statewide BOP Protocols](#).

- Nicotine Replacement Therapy

- Hormonal Contraception
- Prenatal Vitamin
- Glucagon
- HIV PEP

Immunizing pharmacists are encouraged to enroll as NC Medicaid providers. The Pharmacy Newsletter regularly includes information about the January 2024 start of Immunizing Pharmacist enrollment as an Ordering Prescribing Referring (OPR) provider. The article titled “Immunizing Pharmacist Enrollment in NC Medicaid Contraceptives and NRT Protocol Reimbursement to Pharmacies” was most recently in the [February 2026 Pharmacy Newsletter](#). The article provides information on enrollment and reimbursement for services provided under the protocols.

72-Hour Emergency Supply Available for Pharmacy Prior Authorization Drugs

Pharmacy providers are encouraged to use the 72-hour emergency supply allowed for drugs requiring prior approval. **Federal law requires that this emergency supply be available to Medicaid beneficiaries for drugs requiring prior approval** (Social Security Act, Section 1927, [42 U.S.C. 1396r-8\(d\)\(5\)\(B\)](#)). Use of this emergency supply will ensure access to medically necessary medications.

The system will bypass the prior approval requirement if an emergency supply is indicated. **Enter “3” in the Level of Service field (418-DI) to indicate that the transaction is an emergency fill.**

Note: Applicable copayments will apply. There is no limit to the number of times the emergency supply can be used.

Checkwrite Schedule for October 2026

Electronic Cutoff Date	Checkwrite Date
Oct. 1, 2026	Oct. 6, 2026
Oct. 8, 2026	Oct. 14, 2026
Oct. 15, 2026	Oct. 20, 2026
Oct. 22, 2026	Oct. 27, 2026

POS claims must be transmitted and processed by 11:59 p.m. on the electronic cutoff date to be included in the next checkwrite.

The 2026 checkwrite schedules for both NC Medicaid and DMH/DPH/ORH are available under the [Quick Links](#) on the right side of the NCTracks home page.

Reminder: As stated in the published approved 2026 checkwrite schedule, "NCTracks will issue 50 checkwrites per fiscal year. The payment cycle is weekly, with exceptions during the last week of June (end of State fiscal year) and the last week of the calendar year."

The last checkwrite date for the State fiscal year was June 23, 2026. There was no checkwrite on June 30, 2026. The first checkwrite for the new State fiscal year was on July 7, 2026.

Preferred Drug List (PDL) Changes - Effective October 1, 2026

In 2009, the North Carolina Department of Health and Human Services (NCDHHS) established the NC Medicaid Preferred Drug List (PDL) to ensure access to cost-efficient, medically appropriate drug therapies that maximize patient health outcomes for all NC Medicaid beneficiaries.

The PDL Review Panel was established the following year to review PDL recommendations received from NCDHHS, NC Medicaid and the Physician Advisory Group Pharmacy and Therapeutics (PAG P&T) Committee to classify prescription medications as preferred or nonpreferred on the PDL.

The NC Medicaid PDL Panel currently meets quarterly, with PDL changes taking effect on the 1st day January, April, July, and October. Ad hoc PDL changes may be made in the interim to address patient safety, product shortages, or products with a significant financial impact.

Below is a summary of the PDL changes effective **Oct. 1, 2026**:

ANALGESICS

- Neuropathic Pain
 - Tonmya Sublingual Tablet moved from Skeletal Muscle Relaxants

ANTICONVULSANTS

- Carbamazepine Derivatives
 - Trileptal Suspension moved to Non-Preferred
- Second Generation
 - Lacosamide Solution moved to Preferred

ANTI-INFECTIVES, SYSTEMIC; ANTIBIOTICS

- Lincosamides and Oxazolidinones
 - Linezolid Suspension moved to Non-Preferred
 - Zyvox Suspension moved to Preferred
- Macrolides and Ketolides
 - E.E.S. 200 mg Suspension moved to Non-Preferred
 - Erythromycin EC Capsule moved to Non-Preferred
- Nitroimidazoles (Gastrointestinal Antibiotics)
 - Neomycin Tablet moved to Preferred
 - Tinidazole Tablet moved to Preferred
- Antivirals (Hepatitis C Agents)
 - Vosevi Tablet moved to Non-Preferred
- Antivirals (Influenza)
 - Rimantadine Tablet moved to Non-Preferred

CARDIOVASCULAR

- Beta Blockers
 - Hemangeol Solution moved to Non-Preferred
- PCSK9
 - Praluent Pen added to Preferred
 - Evekeeza IV, Redemplo Syringe, Tryngolza Autoinjector added to Non-Preferred

ENDOCRINOLOGY

- Glucagon Agents (New PDL Class)
 - Added as Preferred: Baqsimi Nasal Spray, Glucagon Emergency Kit (all manufacturers except Amphastar), Gvoke Pen/Syringe/Vial, Proglycem Oral Suspension
 - Added as Non-Preferred: Diazoxide Oral Suspension, Glucagon Emergency Kit (Manufacturer: Amphastar), Glucagon Injection, Zegalogue Syringe/Autoinjector
- Premixed 70/30 Combination Insulin
 - Novolog Mix 70/30 Vial/FlexPen moved to Preferred
- GLP-1 Receptor Agonists and Combinations Indicated for the Treatment of Diabetes
 - Mounjaro Pen moved to Preferred
- Octreotides and Related (New PDL Class)
 - Added as Preferred: Octreotide acetate Ampule/Syringe, Sandostatin LAR Depot Vial

- Added as Non-Preferred: Lanreotide acetate syringe, Mycapssa Capsule, Octreotide acetate Vial, Palsonify Tablet, Signifor Injection, Signifor LAR Injection, Somatuline Depot Injection

GASTROINTESTINAL

- H. Pylori Combinations
 - Voquezna Tablet/Dual Pak and Triple Pak moved to Preferred
- Selective Constipation Agents
 - Prucalopride Tablet moved to Preferred
- Ulcerative Colitis: Oral
 - Mesalamine ER Capsule moved to Preferred

GENITOURINARY/RENAL

- Urinary Antispasmodics
 - Darifenacin ER Tablet moved to Preferred
 - Trospium Tablet/ER Capsule moved to Preferred

OPHTHALMIC

- Anti-Inflammatory
 - Ketorolac Solution moved to Preferred

OSTEOPOROSIS

- Bone Resorption Suppression and Related Agents
 - Enoby Syringe moved to Preferred
 - Bildyos Syringe moved to Non-Preferred

RESPIRATORY

- Intranasal Rhinitis Agents
 - Mometasone Nasal Spray moved to Preferred

TOPICALS

- Acne Agents
 - Tretinoin Cream moved to Preferred
- Androgenic Agents
 - Testosterone Gel Packet (generic for Vogelxo) moved to Preferred
- Antibiotics – Vaginal
 - Xaciatto Vaginal Gel moved to Preferred
 - Clindesse Vaginal Cream moved to Non-Preferred
- Antiparasitics
 - Spinosad Topical Suspension moved to Preferred
- Psoriasis
 - Vtama Cream moved to Preferred

MISCELLANEOUS

- Weight Management Agents
 - Wegovy HD, Foundayo Tablet added to Preferred
 - Zepbound Pen/Kwikpen moved to Preferred
- Immunomodulators, Asthma
 - Tezspire Pen/Syringe, Xolair Vial moved to Preferred
- Oral/Transdermal Estrogen Agents and Other
 - Lynkuet Capsule moved to Preferred
- Potassium Binders (New PDL Class)
 - Added to Preferred: Lokelma Powder, SPS Suspension, Sodium polystyrene sulfonate Powder
 - Added to Non-Preferred: Lokelma Unit Dose, Kionex Suspension, Veltassa Powder

Preferred Brands with Non-Preferred Generics on the Preferred Drug List (PDL) Current as of October 1, 2026

Brand Name	Generic Name
ACTIVELLA 1 MG-0.5 MG TABLET	ABIGALE 1 MG-0.5 MG TABLET
ADVAIR 100-50 DISKUS	FLUTICASONE-SALMETEROL 100-50
ADVAIR 100-50 DISKUS	WIXELA 100-50 INHUB
ADVAIR 250-50 DISKUS	FLUTICASONE-SALMETEROL 250-50
ADVAIR 250-50 DISKUS	WIXELA 250-50 INHUB
ADVAIR 500-50 DISKUS	FLUTICASONE-SALMETEROL 500-50
ADVAIR 500-50 DISKUS	WIXELA 500-50 INHUB
ADVAIR HFA 115-21 MCG INHALER	FLUTICASONE-SALMETEROL 115-21
ADVAIR HFA 230-21 MCG INHALER	FLUTICASONE-SALMETEROL 230-21
ADVAIR HFA 45-21 MCG INHALER	FLUTICASONE-SALMETEROL 45-21
ALPHAGAN P 0.1% DROPS	BRIMONIDINE TARTRATE 0.1% DROP
ALPHAGAN P 0.15% EYE DROPS	BRIMONIDINE TARTRATE 0.15% DRP
ANORO ELLIPTA 62.5-25 MCG INH	UMECLIDINIUM-VILANTERO 62.5-25
ARNUITY ELLIPTA 100 MCG INH	FLUTICASONE ELLIPTA 100MCG INH
ARNUITY ELLIPTA 200 MCG INH	FLUTICASONE ELLIPTA 200MCG INH
ARNUITY ELLIPTA 50 MCG INH	FLUTICASONE ELLIPTA 50 MCG INH
ATROVENT 17 MCG HFA INHALER	IPRATROPIUM BR 17 MCG HFA INH
BETHKIS 300 MG/4 ML AMPULE	TOBRAMYCIN 300 MG/4 ML AMPULE
BRIVIACT 10 MG TABLET	BRIVARACETAM 10 MG TABLET
BRIVIACT 10 MG/ML ORAL SOLN	BRIVARACETAM 10 MG/ML ORAL SOL
BRIVIACT 100 MG TABLET	BRIVARACETAM 100 MG TABLET
BRIVIACT 25 MG TABLET	BRIVARACETAM 25 MG TABLET

BRIVIACT 50 MG TABLET	BRIVARACETAM 50 MG TABLET
BRIVIACT 75 MG TABLET	BRIVARACETAM 75 MG TABLET
BUPHENYL 500 MG TABLET	SODIUM PHENYLBUTYRATE 500MG TB
BUPHENYL POWDER	SODIUM PHENYLBUTYRATE POWDER
BUTRANS 10 MCG/HR PATCH	BUPRENORPHINE 10 MCG/HR PATCH
BUTRANS 15 MCG/HR PATCH	BUPRENORPHINE 15 MCG/HR PATCH
BUTRANS 20 MCG/HR PATCH	BUPRENORPHINE 20 MCG/HR PATCH
BUTRANS 5 MCG/HR PATCH	BUPRENORPHINE 5 MCG/HR PATCH
BUTRANS 7.5 MCG/HR PATCH	BUPRENORPHINE 7.5 MCG/HR PATCH
BYETTA 10 MCG DOSE PEN INJ	EXENATIDE 10 MCG DOSE PEN INJ
BYETTA 5 MCG DOSE PEN INJ	EXENATIDE 5 MCG DOSE PEN INJ
CARBAGLU 200 MG TAB FOR SUSP	CARGLUMIC ACID 200 MG TAB SUSP
CELONTIN 300 MG CAPSULE	METHSUXIMIDE 300 MG CAPSULE
CIPRO 10% SUSPENSION	CIPROFLOXACIN 500 MG/5 ML SUSP
CIPRO 5% SUSPENSION	CIPROFLOXACIN 250 MG/5 ML SUSP
COMBIGAN 0.2%-0.5% EYE DROPS	BRIMONIDINE-TIMOLOL 0.2%-0.5%
COPAXONE 20 MG/ML SYRINGE	GLATIRAMER 20 MG/ML SYRINGE
COPAXONE 20 MG/ML SYRINGE	GLATOPA 20 MG/ML SYRINGE
DENAVIR 1% CREAM	PENCICLOVIR 1% CREAM
DERMA-SMOOTH-FS BODY OIL	FLUOCINOLONE 0.01% BODY OIL
DERMA-SMOOTH-FS SCALP OIL	FLUOCINOLONE 0.01% SCALP OIL
DICLEGIS DR 10-10 MG TABLET	DOXYLAMINE-PYRIDOXINE 10-10 MG
DIFFERIN 0.1% CREAM	ADAPALENE 0.1% CREAM
DIFFERIN 0.3% GEL PUMP	ADAPALENE 0.3% GEL PUMP
DYMISTA NASAL SPRAY	AZELASTIN-FLUTIC 137-50MCG SPR
EMFLAZA 18 MG TABLET	DEFLAZACORT 18 MG TABLET
EMFLAZA 18 MG TABLET	JAYTHARI 18 MG TABLET
EMFLAZA 18 MG TABLET	KYMBEE 18 MG TABLET
EMFLAZA 22.75 MG/ML ORAL SUSP	DEFLAZACORT 22.75 MG/ML SUSP
EMFLAZA 22.75 MG/ML ORAL SUSP	JAYTHARI 22.75 MG/ML ORAL SUSP
EMFLAZA 22.75 MG/ML ORAL SUSP	KYMBEE 22.75 MG/ML ORAL SUSP
EMFLAZA 22.75 MG/ML ORAL SUSP	PYQUVI 22.75 MG/ML ORAL SUSP
EMFLAZA 30 MG TABLET	DEFLAZACORT 30 MG TABLET
EMFLAZA 30 MG TABLET	JAYTHARI 30 MG TABLET
EMFLAZA 30 MG TABLET	KYMBEE 30 MG TABLET
EMFLAZA 36 MG TABLET	DEFLAZACORT 36 MG TABLET
EMFLAZA 36 MG TABLET	JAYTHARI 36 MG TABLET
EMFLAZA 36 MG TABLET	KYMBEE 36 MG TABLET
EMFLAZA 6 MG TABLET	DEFLAZACORT 6 MG TABLET
EMFLAZA 6 MG TABLET	JAYTHARI 6 MG TABLET
EMFLAZA 6 MG TABLET	KYMBEE 6 MG TABLET
EPRONTIA 25 MG/ML SOLUTION	TOPIRAMATE 25 MG/ML SOLUTION
EXELON 13.3 MG/24HR PATCH	RIVASTIGMINE 13.3 MG/24HR PTCH

EXELON 4.6 MG/24HR PATCH	RIVASTIGMINE 4.6 MG/24HR PATCH
EXELON 9.5 MG/24HR PATCH	RIVASTIGMINE 9.5 MG/24HR PATCH
FARXIGA 10 MG TABLET	DAPAGLIFLOZIN 10 MG TABLET
FARXIGA 5 MG TABLET	DAPAGLIFLOZIN 5 MG TABLET
FELBATOL 400 MG TABLET	FELBAMATE 400 MG TABLET
FELBATOL 600 MG TABLET	FELBAMATE 600 MG TABLET
FORTEO 560 MCG/2.24 ML PEN INJ	TERIPARATIDE 560MCG/2.24ML PEN
FYCOMPA 0.5 MG/ML ORAL SUSP	PERAMPANEL 0.5 MG/ML ORAL SUSP
FYCOMPA 10 MG TABLET	PERAMPANEL 10 MG TABLET
FYCOMPA 12 MG TABLET	PERAMPANEL 12 MG TABLET
FYCOMPA 2 MG TABLET	PERAMPANEL 2 MG TABLET
FYCOMPA 4 MG TABLET	PERAMPANEL 4 MG TABLET
FYCOMPA 6 MG TABLET	PERAMPANEL 6 MG TABLET
FYCOMPA 8 MG TABLET	PERAMPANEL 8 MG TABLET
INCRUSE ELLIPTA 62.5 MCG INH	UMECLIDINIUM ELLIPTA 62.5 MCG
JANUMET 50-1,000 MG TABLET	SITAGLIPTIN PHOS-METF 50-1,000
JANUMET 50-500 MG TABLET	SITAGLIPTIN PHOS-METF 50-500
JANUMET XR 100-1,000 MG TABLET	SITAGLIP PHOS-METF ER 100-1000
JANUMET XR 50-1,000 MG TABLET	SITAGLIP PHOS-METF ER 50-1,000
JANUMET XR 50-500 MG TABLET	SITAGLIP PHOS-METF ER 50-500
JANUVIA 100 MG TABLET	SITAGLIPTIN PHOS 100 MG TABLET
JANUVIA 25 MG TABLET	SITAGLIPTIN PHOSPHATE 25 MG TB
JANUVIA 50 MG TABLET	SITAGLIPTIN PHOSPHATE 50 MG TB
KITABIS PAK 300 MG/5 ML	TOBRAMYCIN PAK 300 MG/5 ML
LOTEMAX 0.5% EYE DROPS	LOTEPREDNOL ETABONATE 0.5% DRP
MYRBETRIQ ER 25 MG TABLET	MIRABEGRON ER 25 MG TABLET
MYRBETRIQ ER 50 MG TABLET	MIRABEGRON ER 50 MG TABLET
NEXIUM DR 10 MG PACKET	ESOMEPRAZOLE DR 10 MG PACKET
NEXIUM DR 2.5 MG PACKET	ESOMEPRAZOLE DR 2.5 MG PACKET
NEXIUM DR 20 MG PACKET	ESOMEPRAZOLE DR 20 MG PACKET
NEXIUM DR 40 MG PACKET	ESOMEPRAZOLE DR 40 MG PACKET
NEXIUM DR 5 MG PACKET	ESOMEPRAZOLE DR 5 MG PACKET
NUVESSA VAGINAL 1.3% GEL	METRONIDAZOLE VAGINAL 1.3% GEL
OXTELLAR XR 150 MG TABLET	OXCARBAZEPINE ER 150 MG TABLET
OXTELLAR XR 300 MG TABLET	OXCARBAZEPINE ER 300 MG TABLET
OXTELLAR XR 600 MG TABLET	OXCARBAZEPINE ER 600 MG TABLET
OXYCONTIN ER 10 MG TABLET	OXYCODONE HCL ER 10 MG TABLET
OXYCONTIN ER 20 MG TABLET	OXYCODONE HCL ER 20 MG TABLET
OXYCONTIN ER 40 MG TABLET	OXYCODONE HCL ER 40 MG TABLET
OXYCONTIN ER 80 MG TABLET	OXYCODONE HCL ER 80 MG TABLET
PREMARIN 0.3 MG TABLET	CONJUGATED ESTROGENS 0.3 MG TB
PREMARIN 0.45 MG TABLET	CONJUGATED ESTROGENS 0.45MG TB
PREMARIN 0.625 MG TABLET	CONJUGATED ESTROGEN 0.625MG TB

PREMARIN 0.9 MG TABLET	CONJUGATED ESTROGENS 0.9 MG TB
PREMARIN 1.25 MG TABLET	CONJUGATED ESTROGENS 1.25MG TB
PROGLYCEM 50 MG/ML ORAL SUSP	DIAZOXIDE 50 MG/ML ORAL SUSP
PROMACTA 12.5 MG SUSPEN PACKET	ELTROMBOPAG 12.5 MG SUSP PKT
PROMACTA 12.5 MG TABLET	ELTROMBOPAG 12.5 MG TABLET
PROMACTA 25 MG SUSPENSION PCKT	ELTROMBOPAG 25 MG SUSP PACKET
PROMACTA 25 MG TABLET	ELTROMBOPAG 25 MG TABLET
PROMACTA 50 MG TABLET	ELTROMBOPAG 50 MG TABLET
PROMACTA 75 MG TABLET	ELTROMBOPAG 75 MG TABLET
PROTONIX 40 MG SUSPENSION	PANTOPRAZOLE DR 40 MG SUSP PKT
PROVIGIL 100 MG TABLET	MODAFINIL 100 MG TABLET
PROVIGIL 200 MG TABLET	MODAFINIL 200 MG TABLET
PYLERA 140-125-125 MG CAPSULE	BISMUTH-METRO-TETR 140-125-125
PYZCHIVA 45 MG/0.5 ML VIAL	USTEKINUMAB-TTWE 45MG/0.5ML VL
RESTASIS 0.05% EYE EMULSION	CYCLOSPORINE 0.05% EYE EMULS
SABRIL 500 MG TABLET	VIGABATRIN 500 MG TABLET
SABRIL 500 MG TABLET	VIGADRONE 500 MG TABLET
SANDOSTATIN LAR DEPOT 10 MG KT	OCTREOTIDE ACET ER 10 MG IM VL
SANDOSTATIN LAR DEPOT 10 MG VL	OCTREOTIDE ACET ER 10 MG IM VL
SANDOSTATIN LAR DEPOT 20 MG KT	OCTREOTIDE ACET ER 20 MG IM VL
SANDOSTATIN LAR DEPOT 20 MG VL	OCTREOTIDE ACET ER 20 MG IM VL
SANDOSTATIN LAR DEPOT 30 MG KT	OCTREOTIDE ACET ER 30 MG IM VL
SANDOSTATIN LAR DEPOT 30 MG VL	OCTREOTIDE ACET ER 30 MG IM VL
SF ROWASA 4 GM/60 ML ENEMA	MESALAMINE 4 GM/60 ML ENEMA
SPIRIVA HANDIHALER 18 MCG CAP	TIOTROPIUM 18 MCG CAP-INHALER
SUBOXONE 12 MG-3 MG SL FILM	BUPRENORPHINE-NALOX 12-3MG FLM
SUBOXONE 2 MG-0.5 MG SL FILM	BUPRENORPHINE-NALOX 2-0.5MG FM
SUBOXONE 4 MG-1 MG SL FILM	BUPRENORPHINE-NALOX 4-1MG FILM
SUBOXONE 8 MG-2 MG SL FILM	BUPRENORPHINE-NALOX 8-2MG FILM
SYMBICORT 160-4.5 MCG INHALER	BREYNA 160-4.5 MCG INHALER
SYMBICORT 160-4.5 MCG INHALER	BUDESONIDE-FORMOTEROL 160-4.5
SYMBICORT 80-4.5 MCG INHALER	BREYNA 80-4.5 MCG INHALER
SYMBICORT 80-4.5 MCG INHALER	BUDESONIDE-FORMOTEROL 80-4.5
TEKTRNA 300 MG TABLET	ALISKIREN 300 MG TABLET
TRACLEER 125 MG TABLET	BOSENTAN 125 MG TABLET
TRACLEER 62.5 MG TABLET	BOSENTAN 62.5 MG TABLET
TRAVATAN Z 0.004% EYE DROP	TRAVOPROST 0.004% EYE DROP
VAGIFEM 10 MCG VAGINAL TAB	ESTRADIOL 10 MCG VAGINAL INSRT
VAGIFEM 10 MCG VAGINAL TAB	YUVAFEM 10 MCG VAGINAL INSERT
VAGIFEM 10 MCG VAGINAL TAB	YUVAFEM 10 MCG VAGINAL TABLET
VICTOZA 2-PAK 18 MG/3 ML PEN	LIRAGLUTIDE 18 MG/3 ML PEN
VICTOZA 2-PAK 18 MG/3 ML PEN	LIRAGLUTIDE 2-PAK 18 MG/3 ML
VICTOZA 2-PAK 18 MG/3 ML PEN	LIRAGLUTIDE 3-PAK 18 MG/3 ML

VICTOZA 3-PAK 18 MG/3 ML PEN	LIRAGLUTIDE 18 MG/3 ML PEN
VICTOZA 3-PAK 18 MG/3 ML PEN	LIRAGLUTIDE 2-PAK 18 MG/3 ML
VICTOZA 3-PAK 18 MG/3 ML PEN	LIRAGLUTIDE 3-PAK 18 MG/3 ML
VYVANSE 10 MG CAPSULE	LISDEXAMFETAMINE 10 MG CAPSULE
VYVANSE 20 MG CAPSULE	LISDEXAMFETAMINE 20 MG CAPSULE
VYVANSE 30 MG CAPSULE	LISDEXAMFETAMINE 30 MG CAPSULE
VYVANSE 40 MG CAPSULE	LISDEXAMFETAMINE 40 MG CAPSULE
VYVANSE 50 MG CAPSULE	LISDEXAMFETAMINE 50 MG CAPSULE
VYVANSE 60 MG CAPSULE	LISDEXAMFETAMINE 60 MG CAPSULE
VYVANSE 70 MG CAPSULE	LISDEXAMFETAMINE 70 MG CAPSULE
XARELTO 2.5 MG TABLET	RIVAROXABAN 2.5 MG TABLET
XELJANZ 10 MG TABLET	TOFACITINIB 10 MG TABLET
XELJANZ 5 MG TABLET	TOFACITINIB 5 MG TABLET
XIGDUO XR 10 MG-1,000 MG TAB	DAPAGLIFLOZIN-METFO ER 10-1000
XIGDUO XR 10 MG-500 MG TABLET	DAPAGLIFLOZIN-METFOR ER 10-500
XIGDUO XR 5 MG-1,000 MG TABLET	DAPAGLIFLOZIN-METFOR ER 5-1000
XIGDUO XR 5 MG-500 MG TABLET	DAPAGLIFLOZIN-METFOR ER 5-500
XOPENEX HFA 45 MCG INHALER	LEVALBUTEROL TAR HFA 45MCG INH
ZYVOX 100 MG/5 ML SUSPENSION	LINEZOLID 100 MG/5 ML SUSP

When a PDL class includes a preferred brand and a non-preferred generic, providers requesting prior approval for the non-preferred generic should provide a clinical rationale explaining why the beneficiary cannot use the preferred brand.

John Matta, PharmD, MBA

Director of Pharmacy and Ancillary Services
NC Medicaid
Division of Health Benefits
N.C. Department of Health and Human Services

Kelley Switzer, PharmD

Pharmacy Director
Prime Therapeutics
Account Management

Angela Smith, PharmD, DHA, MHA

Chief Clinical Officer, NC Medicaid
Division of Health Benefits
N.C. Department of Health and Human Services

VACANT

Chief Medical Officer, NC Medicaid
Division of Health Benefits
N.C. Department of Health and Human Services

Melanie Bush

Deputy Secretary, NC Medicaid
Division of Health Benefits
N.C. Department of Health and Human Services

Julie F. Brown, PsyD, MBA, LMSW

Director of Education and Outreach
Prime Therapeutics
Account Management

October 2026

Leslie Pittman, PharmD

Sr. Director

Prime Therapeutics

Account Management